Research Use Disclaimer

You must be 21 or older. Agree to the following terms before accessing product information and pricing.

Research Use Policy Summary

You are 21 years of age or older
All products sold exclusively for laboratory research purposes
Products are not intended for human consumption, diagnosis, or therapeutic use
Purchasers must be qualified researchers or licensed professionals
These products have not been evaluated or approved by the FDA
All sales are final and subject to our research use terms

For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.

Read full Research Use Disclaimer (opens in new tab) →

Product Usage Notice · This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such. Read full Research Use Policy →

Compound Information

Technical specifications

Molecular Profile

What Is Tesamorelin?

Tesamorelin is a synthetic GHRH analog modified with a trans-3-hexenoic acid moiety for improved stability, studied in preclinical models of the somatotropic axis and lipid metabolism signaling.

Type: Peptide
CAS Number: 218949-48-5
Molecular Weight: 5135.91 g/mol
Amino Acids: 44 residues
Formula: C221H366N72O67S

PubChem Database

TESAMORELIN · 2007

Metabolic Effects of a Growth Hormone-Releasing Factor — Falutz et al., New England Journal of Medicine (2007). Randomized controlled study examining GH-axis modulation by a GHRH analog; reported changes in visceral adipose tissue volume, IGF-1 levels, and lipid pathway markers in a controlled model. Cited for scientific context of GHRH receptor pharmacology only; it does not provide use guidance or product claims for this research compound.

View Study

TESAMORELIN · 2014

Tesamorelin Research in Lipolysis and Hepatic Lipid Metabolism Pathways JAMA Published pharmacology literature examining GHRH-mediated lipolysis pathway pharmacology. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

TESAMORELIN · 2019

Tesamorelin Research in Hepatic Lipid Metabolism Pathway Literature Published pharmacology literature examining hepatic lipid metabolism pathways. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

TESAMORELIN · 2020

Tesamorelin and GHRH-Mediated Vascular Pathway Marker Research Journal of Endocrinology & Metabolism Published pharmacology literature examining GHRH-mediated pathway markers. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

TESAMORELIN · 2012

Growth Hormone-Releasing Hormone and CNS Pathway Research Archives of Neurology Published pharmacology literature examining GHRH receptor-mediated CNS pathway effects. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.

View Study

TESAMORELIN · 2021

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways — Stanley et al., Clinical Infectious Diseases (2021). Proteomics and transcriptomics analysis of a GHRH analog examining downstream cytokine and chemokine pathway modulation, T-cell activation marker changes, and hepatic immune gene-set signaling in a controlled model. Cited for scientific context of GHRH-mediated immune pathway signaling only; it does not provide use guidance or product claims for this research compound.

View Study